Skip to main content

Cutaneous human Papilloma Virus Vaccine

Ref-Nr: TA-P-1358


Kurzfassung

The technology comprises an immunogenic polypeptide comprising a multitude of papillomavirus (PV) L2 N-terminal peptides, corresponding to amino acids 20 to 50 of the L2 polypeptide of HPV16, wherein said HPV L2 N-terminal peptides are L2 N-terminal peptides from at least four different cutaneous HPV genotypes; and to the aforesaid immunogenic polypeptide for use in medicine and for use in vaccination of a subject against cutaneous HPV infection and/or mucosal HPV infection. The technology further comprises a polynucleotide encoding the aforesaid immunogenic polypeptide and to vectors, host cells, methods for producing an antibody, as well as antibodies related thereto.


Hintergrund

Infections with human papillomavirus (HPV) are a worldwide health challenge, particularly in resource-limited regions. HPV-related diseases are premalignancies or overt malignancies of the skin and mucosal surfaces and are an important personal and public health problem causing physical, mental, sexual and financial detriments. The World Health Organization estimates that there are approximately 14 million new HPV infections each year. Currently, ~200 different HPV genotypes are described with varying tropism for anogenital mucosa or skin. Skin warts are found in a small fraction of healthy adults and these are caused by HPV from different genera. While ß-papillomaviruses are among the most abundant HPV in the skin, they do not cause lesions in healthy individuals. In organ transplant recipients (OTRs) the number of skin warts is constantly rising, corresponding with the duration of the iatrogenic immune suppression. Similar observations are being made in other immune compromised individuals, e.g. HIV+. Five years after transplantation up to 92% of the OTRs are suffering from skin warts. Skin warts constitute a significant burden and reduced quality of life in OTRs due to their confluent occurrence at multiple body sites. The warts in OTRs usually do not regress spontaneously and therefore require repeated and costly treatment which, however, can only alleviate the symptoms and does not provide a lasting cure. There is, thus, a need in the art for improved means and methods for vaccination against HPV, in particular cutaneous HPV, and in particular for immunogenic polypeptides that are highly immunogenic and allow for a cross-neutralization of various HPV genotypes without the drawbacks as referred to above. Thus we have developed an immunogenic polypeptide comprising a multitude of papillomavirus (PV) L2 N-terminal peptides to protect against most cutaneous HPV types


Bilder & Videos


Lösung

An improved immunogenic polypeptide comprising a multitude of papillomavirus (PV) L2 N-terminal peptides to protect against most cutaneous HPV types which allows for a cross-neutralization of various HPV genotypes.


Vorteile

Treatment of infections with cutaneous HPV types before organ transplantation


Anwendungsbereiche

  • Pharmaceutical composition
  • Vaccine 

Deutsches Krebsforschungszentrum DKFZ

Dr. Frieder Kern
+49-6221-42-2952
f.kern@dkfz.de
www.dkfz.de
Adresse
Im Neuenheimer Feld 280
69120 Heidelberg



Entwicklungsstand

Präklinik


Stichworte

Therapeutics, Vaccines, HPV, cutaneous

Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TechnologieAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsstellenleiterin)

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr